Who Owns the Cardiovascular-Kidney-Metabolic Patient Before the Event Occurs? A Multidisciplinary Approach to Early Intervention and Prevention

The increasing overlap between cardiovascular disease, chronic kidney disease (CKD), and type 2 diabetes (T2D) has transformed the way healthcare professionals approach patient management. Rather than treating these conditions in isolation, there is growing recognition that optimal outcomes require a coordinated, multidisciplinary strategy that addresses the interconnected cardio-kidney-metabolic (CKM) continuum before irreversible clinical events occur.

This training course is designed to equip healthcare professionals with the latest evidence-based knowledge and practical strategies for the early identification, comprehensive assessment, and management of patients at risk of cardiovascular and kidney complications associated with CKD and T2D. Participants will explore the shared pathophysiological mechanisms that drive disease progression, including hemodynamic, metabolic, inflammatory, and fibrotic pathways, and understand how timely intervention can significantly improve patient outcomes.

A key focus of the course is the role of mineralocorticoid receptor (MR) overactivation in promoting chronic inflammation and fibrosis, accelerating kidney damage, cardiovascular disease, and progression to kidney failure. Participants will review current clinical evidence supporting the use of guideline-directed therapies, including the role of non-steroidal mineralocorticoid receptor antagonists such as finerenone, alongside established standards of care for patients with CKD associated with T2D.

Through expert-led presentations and multidisciplinary discussions, the course will examine how cardiologists, nephrologists, endocrinologists, diabetologists, internists, primary care physicians, pharmacists, nurses, and other healthcare professionals can work collaboratively to identify high-risk patients earlier, optimise treatment pathways, and prevent major cardiovascular and renal events before they occur.

By the end of this course, participants will be able to:

• Understand the interconnected nature of cardiovascular, kidney, and metabolic diseases within the CKM continuum.
• Explain the role of mineralocorticoid receptor overactivation and the contribution of inflammation and fibrosis to CKD and cardiovascular disease progression.
• Apply current evidence and international guideline recommendations for the management of CKD associated with T2D.
• Recognise appropriate patients for comprehensive, evidence-based therapies aimed at reducing kidney disease progression and cardiovascular risk.
• Implement multidisciplinary, patient-centred strategies that promote earlier intervention, improve clinical outcomes, and reduce the burden of cardiovascular and kidney disease.

This course is intended for cardiologists, nephrologists, endocrinologists, diabetologists, internal medicine physicians, family physicians, pharmacists and other healthcare professionals involved in the care of patients with cardiovascular, kidney, and metabolic diseases.

Join leading experts as they explore one of the most important questions in modern medicine: Who owns the Cardiovascular-Kidney-Metabolic patient before the event occurs? Discover why the answer lies not within a single specialty, but in a collaborative, multidisciplinary approach focused on prevention, early intervention, and delivering the right treatment to the right patient at the right time.

WHY YOU SHOULD ATTEND

1. Stay current with the latest evidence on evolving Cardiovascular-Kidney-Metabolic (CKM)

2. Gain insights into the Ghanaian perspective and real-world clinical practice

3. Explore the latest clinical evidence and guideline recommendations

4. Learn how to identify high-risk patients earlier

5. Gain insights into the role of mineralocorticoid receptor overactivation 

6. Earn CPD points accredited by the Medical and Dental Council (MDC) & Pharmacy Council (PC)

EVENT HIGHLIGHTS

i. Expert-led sessions

ii. Focus on practical, real-world CKD management

iii. Insight into innovative combination therapy

iv. Interactive Q&A and panel discussion 

v. Opportunity to earn CPD-accredited learning points 

PARTICIPANT CONSENT AND DATA PRIVACY NOTICE

By registering for this event, you consent to participate in this training hosted by CES on behalf of DP World and Bayer. Your registration will provide us with the necessary information to facilitate the event and issue CPD accreditation through the Medical and Dental Council (MDC) and Pharmacy Council (PC).

Please note that CES is committed to safeguarding your personal information and will not share any personal data with DP World and Bayer. Your data will only be shared with the relevant regulatory bodies, such as MDC & PC, for the sole purpose of accrediting you with CPD points earned through this training.

Additionally, participants are free to opt out of the meeting at any time, and should you wish to do so, no further action is required on your part. We respect your privacy and ensure that your participation will be treated with the highest level of confidentiality.

PROUDLY SPONSORED BY

This is a hybrid event. The CPD event will be streamed LIVE on this page.

Moderator: Dr. Yacoba Atiase

Date:  Thurs. 23rd July, 2026

Time: 1500 GMT (3:00pm local time)

Target Audience: Medical Doctors & Pharmacists

In-person attendance at the Accra City Hotel, Accra.

Don’t miss out on this exciting opportunity to elevate your skills and make a lasting impact!